NLM Citation: Drugs and Lactation Database (LactMed) [Internet].

Bethesda (MD): National Library of Medicine (US); 2006-. Remdesivir.

[Updated 2021 Apr 19].
Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Remdesivir
Revised: April 19, 2021.

CASRN: 1809249-37-3

Drug Levels and Effects

Summary of Use during Lactation
No information is available on the use of remdesivir during breastfeeding. Remdesivir is given intravenously
because it is poorly absorbed orally, so infants are not likely to absorb clinically important amounts of the drug
from milk. In addition, a newborn infants have received intravenous remdesivir therapy for Ebola with no
serious adverse drug reactions.[1,2] Given this limited information, it does not appear that mothers receiving
remdesivir need to avoid nursing, but until more data are available, remdesivir should be used with careful
infant monitoring during breastfeeding.[3] The most common adverse effects reported after intravenous
infusion include elevated aminotransferase and bilirubin levels and other liver enzyme elevations, diarrhea, rash,
renal impairment and hypotension.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should
consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does
not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
2 Drugs and Lactation Database (LactMed)

Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References
1. Dörnemann J, Burzio C, Ronsse A, et al. First newborn baby to receive experimental therapies survives Ebola
virus disease. J Infect Dis. 2017;215:171–4. PubMed PMID: 28073857.
2. Mulangu S, Dodd LE, Davey RT Jr, et al. A randomized, controlled trial of Ebola virus disease therapeutics.
N Engl J Med. 2019;381:2293–303. PubMed PMID: 31774950.
3. Aleissa MM, Silverman EA, Paredes Acosta LM, et al. New perspectives on antimicrobial agents: Remdesivir
treatment for COVID-19. Antimicrob Agents Chemother. 2020;65:e01814–20. PubMed PMID: 33139290.

Substance Identification
Substance Name
Remdesivir

CAS Registry Number

1809249-37-3

Drug Class
Breast Feeding
Lactation
Antimetabolites
Antiviral Agents